Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intravenous immunoglobulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    449 result(s) found for: Intravenous immunoglobulin. Displaying page 9 of 23.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2018-000102-33 Sponsor Protocol Number: 69HCL16_0079 Start Date*: 2018-03-22
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in children: a multicenter European randomized controlled trial
    Medical condition: toxic shock syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10044248 Toxic shock syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2020-001113-21 Sponsor Protocol Number: NDPHRECOVERY Start Date*: 2020-03-17
    Sponsor Name:University of Oxford
    Full Title: Randomised Evaluation of COVID-19 Therapy (RECOVERY)
    Medical condition: COVID-19 (infection with SARS-CoV-2 virus)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    20.1 10021881 - Infections and infestations 10061982 Severe acute respiratory syndrome PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002054-55 Sponsor Protocol Number: PXD101-301-G Start Date*: 2006-01-12
    Sponsor Name:Topotarget A/S
    Full Title: A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma
    Medical condition: Patients in relapse from prior treatment, with histologically and otherwise verified diagnosis of multiple myeloma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000961-36 Sponsor Protocol Number: KB057 Start Date*: 2013-11-15
    Sponsor Name:Kedrion SpA
    Full Title: Tolerability and safety evaluation of the administration of Ig VENA at high infusion rates. Open label phase III study.
    Medical condition: Patients affected by primary or secondary immunodeficiency (ID) or patients affected by Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10054979 Secondary immunodeficiency PT
    16.1 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    16.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000044-22 Sponsor Protocol Number: C1071005 Start Date*: 2021-09-14
    Sponsor Name:Pfizer Inc.
    Full Title: AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALI...
    Medical condition: MULTIPLE MYELOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) PL (Trial now transitioned) ES (Restarted) IT (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001988-36 Sponsor Protocol Number: CCD-LMZYMAA1-08 Start Date*: 2016-10-05
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated velmanase alfa (recombinant human alpha-mannosidase) Treatment in Pediatric Patients below 6 year...
    Medical condition: Alfa-mannosidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10032658 Other specified disorders of carbohydrate transport and metabolism LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004346-42 Sponsor Protocol Number: 3150-301-008 Start Date*: 2019-09-10
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikuma...
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) ES (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BE (Not Authorised) IT (Prematurely Ended) SK (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-000796-16 Sponsor Protocol Number: GAMr-30 Start Date*: 2012-07-09
    Sponsor Name:OCTAPHARMA AG
    Full Title: PROSPECTIVE, OPEN-LABEL, NON-CONTROLLED, MULTICENTER, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCTAGAM 10% IN PRIMARY IMMUNE THROMBOCYTOPENIA
    Medical condition: Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010640-34 Sponsor Protocol Number: THYTOTRA Start Date*: 2009-08-13
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION.
    Medical condition: Adult recipients of first liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024715 Liver transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020931-37 Sponsor Protocol Number: IG0907 Start Date*: 2010-10-01
    Sponsor Name:GRIFOLS S.A.
    Full Title: EFFICACY AND SAFETY OF NIULIVA FOR THE PREVENTION OF HEPATITIS B VIRUS RECURRENCE IN NEWLY ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS
    Medical condition: HBV induced liver disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019731 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000026-31 Sponsor Protocol Number: ML18704 Start Date*: 2006-06-20
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma
    Medical condition: Multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002192-41 Sponsor Protocol Number: E:531/2011 Start Date*: 2012-02-09
    Sponsor Name:University Hospital Tübingen
    Full Title: Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation afte...
    Medical condition: Treatment of patient with advanced hematologic malignancies such as patients with leukemia or lymphoma treatable by allogeneic stem cell transplantation but without a suitable matched donor.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001983-52 Sponsor Protocol Number: GV28985 Start Date*: 2013-09-19
    Sponsor Name:Genentech Inc.
    Full Title: A randomized, double-blind, placebo-controlled, phase 2a study in healthy volunteers, to evaluate the efficacy and safety of MHAA4549A in an Influenza challenge model
    Medical condition: Treatment of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.0 100000004862 10016790 Flu LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016966-97 Sponsor Protocol Number: CAD01 Start Date*: 2010-06-08
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease ...
    Medical condition: Cold agglutinin disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009868 Cold type haemolytic anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011152-22 Sponsor Protocol Number: GTG003.08 Start Date*: Information not available in EudraCT
    Sponsor Name:GENETHON
    Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome
    Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000805-68 Sponsor Protocol Number: GITMO-1 Start Date*: 2005-03-08
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE
    Full Title: A RANDOMISED STUDY TO COMPARE THE REDUCED INTENSIVE REGIMEN CONTAINING ALEMTUZUMAB VERSUS ATG IN ALLOGENIC TRAPIANTS FROM MUD
    Medical condition: CONDITIONING WITH REDUCED INTENSIVE REGIMEN IN ALLOGENI TRANSPLANT FROM MUD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000181-39 Sponsor Protocol Number: C0168X84, EU-0108 Start Date*: 2005-08-31
    Sponsor Name:Med. Universitaetsklinik Graz, ao Univ. Professor Dr. med. Thomas C. Wascher
    Full Title: A Prospective Trial of Anti-TNF-a Chimeric Monoclonal Antibody (infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity
    Medical condition: Insulin Resistant Human Obesity
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003127-62 Sponsor Protocol Number: MuSK-001 Start Date*: 2015-10-02
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis
    Medical condition: Patients with MuSK Antibody Positive Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10062976 Neuromuscular weakness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005609-28 Sponsor Protocol Number: RAV-IgA Start Date*: 2022-03-18
    Sponsor Name:Dr. Alfons Segarra Medrano
    Full Title: A PILOT PROOF-OF–CONCEPT STUDY TO ASSESS THE EFFICACY AND SAFETY OF A 6 MONTHS RAVULIZUMAB TREATMENT IN PATIENTS WITH FLARES OF CORTICOSTEROID-RESISTANT IDIOPATHIC IgA NEPHROPATHY
    Medical condition: Treatment for IgA nephropathy flares
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000447-26 Sponsor Protocol Number: SPK-8011-301 Start Date*: 2019-10-23
    Sponsor Name:Spark Therapeutics, Inc
    Full Title: An Open-label, Non-investigational Product, Multi-center, Lead-in Study to Evaluate Prospective Bleeding and Infusion Data of Current FVIII Replacement Therapy in Adult Males with Hemophilia A
    Medical condition: Hemophilia A
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:23:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA